Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ra Pharmaceuticals, Inc.    RARX

RA PHARMACEUTICALS, INC.

(RARX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price?

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/10/2019 | 08:13am EDT

SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) ("Ra Pharma") breached their fiduciary duties in connection with the proposed sale of the Company to UCB S.A.

On October 10, 2019, Ra Pharma announced that it had signed a definitive merger agreement with UCB. Under the terms of the merger agreement, Ra Pharma shareholders will receive $48.00 in cash for each share of Ra Pharma common stock they own.

The investigation concerns whether the Ra Pharma board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Ra Pharma shares of common stock.

If you are a shareholder of Ra Pharma and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[Click here to join this action]

Cision
View original content:http://www.prnewswire.com/news-releases/ra-pharma-rarx-alert-johnson-fistel-investigates-proposed-sale-of-ra-pharmaceuticals-is-48-a-fair-price-300936450.html

SOURCE Johnson Fistel, LLP


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RA PHARMACEUTICALS, INC.
10/10MARKET SNAPSHOT: Stocks Notch Consecutive Gains As Trump Plans To Meet China'..
DJ
10/10BRAGAR EAGEL & SQUIRE, P.C. IS INVES : RARX) on Behalf of Ra Pharma Shareholders..
PR
10/10WeissLaw LLP Investigates Ra Pharmaceuticals, Inc.
PR
10/10NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/10RA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regulatio..
AQ
10/10RA PHARMA (RARX) ALERT : Johnson Fistel Investigates Proposed Sale of Ra Pharmac..
PR
10/10UCB AGREES TO ACQUIRE RA PHARMACEUTI : Joining Forces to Improve Treatment Optio..
BU
10/02RA PHARMACEUTICALS : Announces Dosing of First Patient in Global Phase 3 Pivotal..
BU
09/18RA PHARMACEUTICALS : Announces Selection for the First ALS Platform Trial by the..
BU
09/04RA PHARMACEUTICALS : Receives Orphan Drug Designation from the U.S. FDA for Zilu..
BU
More news